All Stories

  1. Association Between Language Performance and Functional Status in Patients with Neurocognitive Disorders
  2. Machine learning-assisted resting-state electroencephalography improves diagnostic accuracy in psychiatric disorders: A narrative review
  3. Gustatory dysfunction and oral frailty: Emerging implications for Alzheimer's disease
  4. Associations among self-reported oral health and intrinsic capacity domains in U.S. older adults: analysis from NHANES 2009–2014
  5. Association between periodontal disease and intrinsic capacity in older adults: insights from NHANES 2009–2014
  6. The therapeutic potential of thalassotherapy for enhancing well-being and reducing pharmaceutical costs in individuals with disabilities
  7. Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?
  8. Alzheimer's Disease May Benefit from Olive Oil Polyphenols: A Systematic Review on Preclinical Evidence Supporting the Effect of Oleocanthal on Amyloid-β Load
  9. Corrigendum to “Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence” [Biomed. Pharmacother. 188 (2025) 118199]
  10. Targeting oral frailty indicators of late-life cognitive disorders and depression: a systematic review
  11. Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead
  12. The Effect of a Mediterranean Diet on Arterial Stiffness: A Systematic Review
  13. An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
  14. Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders
  15. The Biological Rationale for Integrating Intrinsic Capacity Into Frailty Models
  16. Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
  17. Oral frailty indicators and cardio- and cerebrovascular diseases in older age: A systematic review
  18. Psychiatry and sensation: the epigenetic links
  19. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  20. Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders
  21. Oral health indicators and bone mineral density disorders in older age: A systematic review
  22. Dietary Intake of Polyphenols and All-Cause Mortality: A Systematic Review with Meta-Analysis
  23. Social Dysfunction and Apathy: Transdiagnostic Domains in Late-Life Cognitive Disorders
  24. Impact of periodontal disease on cognitive disorders, dementia, and depression: a systematic review and meta-analysis
  25. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
  26. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
  27. Multidimensional complex frailty phenotypes: epidemiological impact of oral frailty in older age
  28. Correction to: Ultra‑processed food consumption and nutritional frailty in older age
  29. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  30. The epigenetics of frailty
  31. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  32. The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease
  33. Nutritional patterns as machine learning predictors of liver health in a population of elderly subjects
  34. The Relationship between Oral Health-Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  35. The Relationship between Oral Health‐Related Quality of Life and Body Mass Index in an Older Population from Southern Italy: The Salus in Apulia Study
  36. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders
  37. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies
  38. Exploring the Association of Burning Mouth Syndrome with Depressive and Anxiety Disorders in Middle-Aged and Older Adults: A Systematic Review
  39. Correction to: Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  40. Late-Onset Depression but not Early-Onset Depression may Increase the Risk of All-Cause Mortality in Older Age: 8-Year Follow-Up of the Salus in Apulia Study
  41. Processed foods and diet quality in pregnancy may affect child neurodevelopment disorders: a narrative review
  42. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies
  43. Associations of a biopsychosocial frailty phenotype with all-cause dementia, Alzheimer’s disease, vascular dementia, and other dementias: the Italian PRoject on the Epidemiology of Alzheimer’s disease (IPREA)
  44. Effect of Physical Activity Intervention on Gait Speed by Frailty Condition: A Randomized Clinical Trial
  45. Corrigendum: Dietary customs and social deprivation in an aging population from Southern Italy: A machine learning approach
  46. Corrigendum: Liver health and dementia in an Italian older population: Findings from the Salus in Apulia study
  47. Retinal Microvasculature and Neural Changes and Dietary Patterns in an Older Population in Southern Italy
  48. Effect of change of interleukin-6 over time on gait speed response: Results from the lifestyle interventions and independence for elders study
  49. Serum levels of IL-6 are associated with cognitive impairment in the salus in apulia population-based study
  50. Ultra-processed food consumption and nutritional frailty in older age
  51. Biopsychosocial frailty and mild cognitive impairment subtypes: Findings from the Italian project on the epidemiology of Alzheimer's disease (IPREA)
  52. Passive tau-based immunotherapy for tauopathies
  53. Temporomandibular Disorders as Contributors to Primary Headaches: A Systematic Review
  54. Dietary profiling of physical frailty in older age phenotypes using a machine learning approach: the Salus in Apulia Study
  55. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study
  56. Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study
  57. Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype
  58. Temporomandibular Disorders as a Risk Factor for Suicidal Behavior: A Systematic Review
  59. Oral frailty indicators to target major adverse health-related outcomes in older age: a systematic review
  60. The challenges of anti-tau therapeutics in Alzheimer disease
  61. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
  62. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
  63. Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  64. Motoric Cognitive Risk Syndrome, Subtypes and 8-year all-cause Mortality in Aging Phenotypes: The Salus in Apulia Study
  65. Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach
  66. Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review
  67. Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach
  68. Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy
  69. Frailty and outcome after traumatic brain injury
  70. Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study
  71. The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy
  72. Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study
  73. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
  74. Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study
  75. Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study
  76. Could Epigenetics Play a Role in Suicidal Behavior in Older Age?
  77. Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study
  78. Beverages Consumption and Oral Health in the Aging Population: A Systematic Review
  79. How many frailties exist? – Authors' reply
  80. Associations between nutritional frailty and 8‐year all‐cause mortality in older adults: The Salus in Apulia Study
  81. COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy
  82. Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study
  83. Oral frailty and its determinants in older age: a systematic review
  84. Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides
  85. Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy
  86. Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy
  87. Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy
  88. Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study
  89. How gait influences frailty models and health‐related outcomes in clinical‐based and population‐based studies: a systematic review
  90. Vitamin D in the development and progression of alzheimer’s disease: implications for clinical management
  91. Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study
  92. Oral frailty and neurodegeneration in Alzheimer’s disease
  93. Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty
  94. Late-life depression and its impact on rehabilitation after traumatic injuries
  95. Social Frailty in the COVID-19 Pandemic Era
  96. A multidimensional frailty approach in predicting and preventing dementia
  97. Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy
  98. Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population
  99. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
  100. Age-related hearing loss and neuropathologic burden
  101. The relationship between epigenetics and microbiota in neuropsychiatric diseases
  102. Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults
  103. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
  104. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
  105. Can pharmacotherapy effectively reduce Alzheimer’s related agitation?
  106. Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy
  107. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study
  108. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase
  109. Social determinants of late-life depression epigenetics
  110. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  111. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study
  112. Corrigendum to “Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review” Neurosci. Biobehav. Rev. 95 (2018) 480–498
  113. The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease
  114. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
  115. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
  116. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
  117. Time to test antibacterial therapy in Alzheimer’s disease
  118. Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia
  119. Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging
  120. The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear
  121. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  122. Disease-modifying therapies for tauopathies: agents in the pipeline
  123. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
  124. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease
  125. Understanding frailty to predict and prevent dementia
  126. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  127. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke
  128. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  129. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
  130. The Role of Biomarkers in Psychiatry
  131. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review
  132. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life
  133. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  134. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  135. CYP2D6 genotypes in revolving door patients with bipolar disorders
  136. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
  137. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
  138. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention
  139. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia
  140. Biopsychosocial Frailty and the Risk of Incident Dementia. The Italian Longitudinal Study of Aging
  141. Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes
  142. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
  143. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  144. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
  145. Cognitive frailty: a potential target for secondary prevention of dementia
  146. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
  147. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  148. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  149. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities
  150. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
  151. Emerging biomarkers and screening for cognitive frailty
  152. Genetics of tailored medicine: Focus on CNS drugs
  153. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  154. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  155. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
  156. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  157. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes
  158. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  159. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders
  160. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
  161. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  162. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  163. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder
  164. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  165. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  166. Alternative pharmacological treatment options for agitation in Alzheimer’s disease
  167. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  168. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis
  169. Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients
  170. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance